Yonhap Infomax NewsChong Kun Dang Co. has launched Archela Inc., a new drug development subsidiary focused on three innovative pipelines—CETP inhibitor, GLP-1 agonist, and HDAC6 inhibitor—aiming to drive future growth and global expansion.
#YonhapInfomax #ChongKunDang #Archela #NewDrugDevelopment #CETPInhibitor #GLP1Agonist #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=86667
#YonhapInfomax #ChongKunDang #Archela #NewDrugDevelopment #CETPInhibitor #GLP1Agonist #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=86667
Chong Kun Dang Establishes New Drug Development Subsidiary 'Archela'—Focus on Three Key Pipelines
Chong Kun Dang Co. has launched Archela Inc., a new drug development subsidiary focused on three innovative pipelines—CETP inhibitor, GLP-1 agonist, and HDAC6 inhibitor—aiming to drive future growth and global expansion.